Get the latest news, updates, funding opportunities and essential information for members of the Brigham research community 
Course Overview
Solid organ transplant recipients are at 3-10 times higher risk of cancer compared to non-transplant patients, due to long-standing immunosuppression. Cancer immunotherapy has become a standard therapy for many cancers, but its use in transplant patients is challenging because of safety and efficacy concerns.
While there has been a growing data on Immuno-Oncology (IO) in transplant population, the consensus on IO use in this vulnerable population is lacking. The goals of our conference are to understand the cancer burden in transplant recipients, to learn up-to-date cancer treatment options (especially IO’s) for transplant patients, and to learn patients’ perspectives from those living with cancer post-transplants.
Learning Objectives
- Understand the cancer burden in transplant recipients
- Learn up-to-date cancer treatment options for transplant patients
- Learn patients’ perspectives from those living with cancer post-transplant
Target Audience
This course is targeted to transplant clinicians (nephrologists, hepatologists, surgeons, advanced practitioners, nurses, social workers), oncologists, as well as transplant recipients and their caregivers.
Course Faculty
Course Director
Naoka Murakami
Assistant Professor, Harvard Medical School
Associate Physician, Transplant Nephrology, Brigham and Women’s Hospital
Course Planners
| Ala Abudeyyeh MD Anderson Cancer Center | Christopher Blosser University Washington, Fred Hutch Cancer Institute | Farhad Danesh MD Anderson Cancer Center |
| Sandra Harrmann Mayo Clinic | Edgar Jaime Memorial Sloan Kettering Cancer Center (MSKCC) | Kenar Jhaveri Hofstra/Northwell Health |
| Aleksandra Kukla Mayo Clinic | Sheron Latcha MSKCC | Nelson Leung Mayo Clinic |
Agenda
9:00-9:05
Opening Remarks
9:05-9:30
Immunotherapy for Kidney Transplant Recipients
Nephrology, University of Washington, Seattle
“Cancer Risk in Kidney Transplant Patients”
Nephrology, Brigham and Women’s Hospital, Boston
“Immune Checkpoint Blockade for Kidney Transplant Patients” – International Society of Nephrology (ISN) designated Speaker
9:35-10:45
How to Treat Cancer in Transplant Patients
Oncology, Johns Hopkins University Hospital
“Immunomodulatory Therapy for Kidney Transplant Recipients with Advanced Cutaneous Cancers”
Oncology, Dana Farber Cancer Institute
“Immune Checkpoint Blockade for Renal Transplant Recipients with Cutaneous Squamous Cell Carcinoma”
Oncology, Dana Farber Cancer Institute
“Cellular Therapies for Transplant Patients”
Oncology, MD Anderson Cancer Center
“ImmunoOncology and Biomarkers”
10:50-11:25
Immune Checkpoint Blockade for Liver Transplant Recipients
Hepatology, Mayo Clinic
“Transplant Hepatologist’s Perspective”
Oncology, Houston Methodist Hospital
“Transplant Oncologist’s Perspective”
11:30-12:00
Patients’ Perspectives (Patient Roundtable)
12:00-12:05
Closing Remarks
Registration
Registration for this course is open. Zoom link will be emailed to the registration email address about 1 week before the event date.
Support
